BRPI0812166A2 - Composições úteis para reduzir nefrotoxicidade e métodos de uso das mesmas - Google Patents
Composições úteis para reduzir nefrotoxicidade e métodos de uso das mesmasInfo
- Publication number
- BRPI0812166A2 BRPI0812166A2 BRPI0812166-4A BRPI0812166A BRPI0812166A2 BR PI0812166 A2 BRPI0812166 A2 BR PI0812166A2 BR PI0812166 A BRPI0812166 A BR PI0812166A BR PI0812166 A2 BRPI0812166 A2 BR PI0812166A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- compositions useful
- reducing nephrotoxicity
- nephrotoxicity
- reducing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/753,883 US7658913B2 (en) | 2005-11-28 | 2007-05-25 | Compositions useful for reducing nephrotoxicity and methods of use thereof |
PCT/US2008/064489 WO2008147856A1 (en) | 2007-05-25 | 2008-05-22 | Compositions useful for reducing nephrotoxicity and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0812166A2 true BRPI0812166A2 (pt) | 2015-07-07 |
Family
ID=40076731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0812166-4A BRPI0812166A2 (pt) | 2007-05-25 | 2008-05-22 | Composições úteis para reduzir nefrotoxicidade e métodos de uso das mesmas |
Country Status (10)
Country | Link |
---|---|
US (5) | US7658913B2 (pt) |
EP (1) | EP2162138B1 (pt) |
JP (1) | JP5416095B2 (pt) |
KR (1) | KR20100023901A (pt) |
CN (1) | CN101686991A (pt) |
AU (1) | AU2008256808B2 (pt) |
BR (1) | BRPI0812166A2 (pt) |
CA (1) | CA2687574C (pt) |
MX (1) | MX2009012523A (pt) |
WO (1) | WO2008147856A1 (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7658913B2 (en) * | 2005-11-28 | 2010-02-09 | Verrow Pharmaceuticals, Inc. | Compositions useful for reducing nephrotoxicity and methods of use thereof |
DK2152078T3 (da) | 2007-04-27 | 2021-02-08 | Cydex Pharmaceuticals Inc | Formuleringer indeholdende clopidogrel og sulfoalkylethercyclodextrin og anvendelsesfremgangsmåder |
US8192721B2 (en) * | 2007-12-13 | 2012-06-05 | Verrow Pharmaceuticals, Inc. | Compositions useful for reducing toxicity associated with gadolinium-based contrast agents |
CN102625658B (zh) | 2009-05-13 | 2015-01-28 | 锡德克斯药物公司 | 包含普拉格雷和环糊精衍生物的药物组合物及其制备和使用方法 |
EP2854531A4 (en) * | 2012-05-30 | 2016-03-23 | Verrow Pharmaceuticals Inc | STABILIZED FORMULATIONS CONTAINING IODIZED CONTRAST AGENTS AND CYCLODEXTRINS |
JP6239282B2 (ja) * | 2013-06-28 | 2017-11-29 | 日本食品化工株式会社 | 腎不全改善剤 |
WO2015147018A1 (ja) * | 2014-03-28 | 2015-10-01 | テルモ株式会社 | 炎症性自己免疫疾患治療用の注射用水性製剤 |
CN104280478B (zh) * | 2014-11-03 | 2016-03-30 | 天津中医药大学 | 内源性小分子物质在快速检测肾毒性方面的应用 |
US10973912B2 (en) | 2015-06-29 | 2021-04-13 | President And Fellows Of Harvard College | Treatment for myopathy |
EP3618825A4 (en) * | 2017-05-03 | 2021-01-20 | Cydex Pharmaceuticals, Inc. | COMPOSITION CONTAINING CYCLODEXTRIN AND BUSULFAN |
CN111419860A (zh) * | 2020-03-19 | 2020-07-17 | 长春市儿童医院 | 一种肾小球分叶状肾病造模方法 |
CN114982708A (zh) * | 2022-05-11 | 2022-09-02 | 成都医学院第一附属医院 | 一种小鼠造影剂肾病模型及其构建方法 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
US4247535A (en) * | 1979-11-05 | 1981-01-27 | American Cyanamid Company | Modified cyclodextrin sulfate salts as complement inhibitors |
US4371673A (en) | 1980-07-21 | 1983-02-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble forms of retinoids |
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
US4654325A (en) * | 1984-05-24 | 1987-03-31 | Selenke William M | Medicament for reducing nephrotoxicity caused by positively charged agents such as aminoglycosides and methods of use thereof |
DK500185A (da) * | 1984-11-02 | 1986-05-03 | Johnson Matthey Plc | Oploeseliggjort platinforbindelse |
US6407079B1 (en) | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
WO1988003923A1 (en) * | 1986-11-25 | 1988-06-02 | Institut Organicheskogo Sinteza Akademii Nauk Latv | 9-substituted guanines |
US4877778A (en) * | 1987-07-01 | 1989-10-31 | The Children's Medical Center Corporation | Method of enhancing lipophile transport using cyclodextrin derivatives |
US5441944A (en) * | 1989-04-23 | 1995-08-15 | The Trustees Of The University Of Pennsylvania | Substituted cyclodextrin sulfates and their uses as growth modulating agents |
US5010092A (en) | 1989-12-22 | 1991-04-23 | Wisconsin Alumni Research Foundation | Protection against chemically-induced kidney damage by methimazole |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
EP0695169B1 (en) * | 1993-04-22 | 2002-11-20 | SkyePharma Inc. | Multivesicular cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
US6540981B2 (en) * | 1997-12-04 | 2003-04-01 | Amersham Health As | Light imaging contrast agents |
US5906981A (en) * | 1996-06-04 | 1999-05-25 | Troy Corporation | Halopropargyl inclusion complexes |
US5780446A (en) * | 1996-07-09 | 1998-07-14 | Baylor College Of Medicine | Formulations of vesicant drugs and methods of use thereof |
FR2754270B1 (fr) | 1996-10-07 | 1998-12-24 | Goemar Lab Sa | Genes codant pour des iota-carraghenases et leur utilisation pour la production d'enzymes de biodegradation des carraghenanes |
JP4865936B2 (ja) * | 1997-03-15 | 2012-02-01 | 中村 敏一 | 急性腎不全治療用hgf |
JPH11100401A (ja) * | 1997-07-30 | 1999-04-13 | Kikkoman Corp | 環状オリゴ糖及びそれを含むレトロウイルス性疾患の予防または治療剤 |
US6077871A (en) * | 1997-11-26 | 2000-06-20 | Pfizer Inc. | Droloxifene pharmaceutical compositions |
US5994409A (en) * | 1997-12-09 | 1999-11-30 | U.S. Bioscience, Inc. | Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds |
JP3229286B2 (ja) * | 1999-04-02 | 2001-11-19 | インターナショナル・ビジネス・マシーンズ・コーポレーション | プリント回路基板の製造方法 |
DK1109806T3 (da) | 1999-07-01 | 2003-12-22 | Italfarmaco Spa | Komplekser af paroxetin med cyclodextriner eller cyclodextrinderivater |
GB9921958D0 (en) | 1999-09-16 | 1999-11-17 | Pharmacia & Upjohn Spa | Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins |
GB9921954D0 (en) | 1999-09-16 | 1999-11-17 | Pharmacia & Upjohn Spa | Formulations for parenteral use of estramustine phosphate with improved pharmacological properties |
KR100358855B1 (ko) * | 2000-02-29 | 2002-10-31 | 광주과학기술원 | 사이클로덱스트린 또는 그 유도체와 조영제의 포접 착체형성 방법 |
KR100362080B1 (ko) | 2000-03-29 | 2002-11-23 | 광주과학기술원 | 고리 올리고당과 그들의 유도체를 이용한 조영제의 새로운포접 착체 |
CN1223378C (zh) | 2000-05-02 | 2005-10-19 | 施万制药 | 含有糖肽抗生素和环糊精的药物组合物 |
US6903100B2 (en) * | 2001-05-03 | 2005-06-07 | Midamerica Neuroscience Research Foundation | Use of regularly scheduled high dose intravenous methotrexate therapy, with interim administration of immunomodulatory agents, to treat multiple sclerosis and other diseases of the central nervous system |
ITMI20012749A1 (it) * | 2001-12-21 | 2003-06-21 | Chiesi Farma Spa | Procedimento per la preparazione mediante trattamento con microonde di composti di inclusione tra farmaco e ciclodestrine e prodotti ottenut |
AU2003215027A1 (en) | 2002-03-21 | 2003-10-08 | Regents Of The University Of Minnesota | Cyclodextrin compositions and methods of treating viral infections |
CA2486141A1 (en) | 2002-05-17 | 2003-11-27 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
US20040048871A1 (en) * | 2002-09-09 | 2004-03-11 | Rowe Vernon D. | Use of high dose intravenous methotrexate, with leucovorin rescue, to treat early multiple sclerosis and other diseases of the central nervous system |
JP2004235128A (ja) | 2002-12-04 | 2004-08-19 | Dainippon Printing Co Ltd | 有機el素子およびその製造方法 |
GB0404487D0 (en) * | 2004-02-28 | 2004-03-31 | Protherics Molecular Design Lt | Use of enzyme |
GB0519391D0 (en) * | 2005-09-22 | 2005-11-02 | Aion Diagnostics Ltd | Imaging agents |
US7658913B2 (en) * | 2005-11-28 | 2010-02-09 | Verrow Pharmaceuticals, Inc. | Compositions useful for reducing nephrotoxicity and methods of use thereof |
ES2473665T3 (es) * | 2005-11-28 | 2014-07-07 | Verrow Pharmaceuticals, Inc. | Composiciones útiles para reducir la nefrotoxicidad y los métodos de uso de las mismas |
JP4008481B2 (ja) * | 2006-08-21 | 2007-11-14 | 独立行政法人科学技術振興機構 | 腎臓の薬物排泄機能に関与する有機アニオントランスポーター |
-
2007
- 2007-05-25 US US11/753,883 patent/US7658913B2/en active Active
-
2008
- 2008-05-22 CA CA2687574A patent/CA2687574C/en active Active
- 2008-05-22 MX MX2009012523A patent/MX2009012523A/es active IP Right Grant
- 2008-05-22 CN CN200880017313A patent/CN101686991A/zh active Pending
- 2008-05-22 JP JP2010509552A patent/JP5416095B2/ja active Active
- 2008-05-22 KR KR1020097027017A patent/KR20100023901A/ko not_active Application Discontinuation
- 2008-05-22 WO PCT/US2008/064489 patent/WO2008147856A1/en active Application Filing
- 2008-05-22 EP EP08756113.0A patent/EP2162138B1/en active Active
- 2008-05-22 AU AU2008256808A patent/AU2008256808B2/en active Active
- 2008-05-22 BR BRPI0812166-4A patent/BRPI0812166A2/pt not_active IP Right Cessation
-
2009
- 2009-12-18 US US12/641,708 patent/US8277779B2/en active Active
-
2010
- 2010-10-13 US US12/903,950 patent/US20110028413A1/en not_active Abandoned
- 2010-10-13 US US12/903,934 patent/US20110027390A1/en not_active Abandoned
-
2012
- 2012-08-23 US US13/592,510 patent/US8574551B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2010528045A (ja) | 2010-08-19 |
AU2008256808A1 (en) | 2008-12-04 |
US20110028413A1 (en) | 2011-02-03 |
JP5416095B2 (ja) | 2014-02-12 |
EP2162138B1 (en) | 2013-08-28 |
MX2009012523A (es) | 2010-02-18 |
US20070270380A1 (en) | 2007-11-22 |
AU2008256808B2 (en) | 2013-07-04 |
EP2162138A1 (en) | 2010-03-17 |
CA2687574C (en) | 2016-04-12 |
KR20100023901A (ko) | 2010-03-04 |
WO2008147856A1 (en) | 2008-12-04 |
CN101686991A (zh) | 2010-03-31 |
CA2687574A1 (en) | 2008-12-04 |
US20100093664A1 (en) | 2010-04-15 |
US20110027390A1 (en) | 2011-02-03 |
AU2008256808A2 (en) | 2010-01-07 |
US20120321564A1 (en) | 2012-12-20 |
EP2162138A4 (en) | 2010-07-28 |
US8574551B2 (en) | 2013-11-05 |
US7658913B2 (en) | 2010-02-09 |
US8277779B2 (en) | 2012-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0812166A2 (pt) | Composições úteis para reduzir nefrotoxicidade e métodos de uso das mesmas | |
BRPI0822104A2 (pt) | Composições antimicrobianas e métodos para o uso das mesmas | |
BRPI0911297A2 (pt) | composição e métodos para preparo e uso das mesmas | |
SMT201600388B (it) | Ligandi leganti opsina, composizioni e metodi d'uso | |
BRPI0813627A2 (pt) | Peptídio antimicrobiano, composições e métodos de uso | |
SMT201500210B (it) | Composizioni applicazioni di gel rimovibili per unghie e metodi per il loro uso | |
BRPI0912703A2 (pt) | composições imuno-moduladoras e métodos para uso dessas | |
BRPI0910852A2 (pt) | composições contendo lipídios e métodos de uso das mesmas | |
SMT201400181B (it) | Composizioni per vasocostrizione e metodi d'uso | |
BRPI0915928A2 (pt) | composições e métodos de uso para anticorpos terapêuticos | |
BRPI0813770A2 (pt) | Composição, e, uso de uma composição | |
BRPI0912717A2 (pt) | Composição farmacêutica, e, uso de 5-azacitidina | |
CU23871B1 (es) | Composiciones y métodos de uso para anticuerpos de dickkopf-1 | |
BRPI0821165A2 (pt) | Uso de uma composição | |
BRPI0913086A2 (pt) | Composições antimicrobianas e métodos de uso | |
BRPI0916630A2 (pt) | composições para uso em construção e processo de aplicação das mesmas | |
BRPI0820556A2 (pt) | Bactéria e métodos para uso das mesmas | |
BRPI0817879A2 (pt) | Composições e métodos de uso de anticorpos contra esclerostina | |
BRPI0817200A2 (pt) | composições oftálmicas sólida e uso de compostos para fabricação de medicamento | |
BRPI0818003A2 (pt) | inibidores de csf-1r, composições e métodos de uso | |
BRPI0821668A2 (pt) | Uso | |
BRPI0813000A2 (pt) | Composições terapêuticas e uso das mesmas | |
BRPI0815407A2 (pt) | Composições e métodos para controlar nematódeos | |
BRPI0813955A2 (pt) | composições terapêuticas e o uso das mesmas | |
BRPI0816350A2 (pt) | Composições orais, produtos e métodos de uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2412 DE 28-03-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |